• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: COVIDIEN VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

COVIDIEN VENA SEAL CLOSURE SYSTEM; AGENT, OCCLUDING, VASCULAR, PERMANENT Back to Search Results
Catalog Number VS-402
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Irritation (1941); Itching Sensation (1943)
Event Date 09/12/2016
Event Type  Injury  
Manufacturer Narrative
A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
On (b)(6) 2016, the physician treated a patient at the great saphenous vein and anterior accessory great saphenous vein using a venaseal device.Ifu was followed.3 veins were treated and all 3 closed.Physician accessed 3 sites - 2 on right and 1 on left.Treated approx.55 cm right gsv.Treated approx.25 cm left gsv.Treated approx.10 cm right accessory vein connected to gsv.It is reported that the day after the procedure the patient began to experience increased redness at treatment site, hot to touch, itchiness and chills.Physician provided nsaids to patient.Additional treatment was then provided - oral steroid, specifically solumedrol (2 courses) and the continued use of benadryl and hydrocortisone cream (at affected areas).On (b)(6) 2016, the patient was still tender and warm to touch but with less redness.Five days later, patient had red itchy hives all over body and a swollen face and eyes.Primary care physician increased oral steroid dosage to 60 mg.On (b)(6) 2016, physician stated the patient had exposure to dermabond without reaction.Patient was responding to oral steroid regimen.Once initial steroid pack was completed, patient's primary physician prescribed a 40 mg treatment of oral steroids.Although symptoms were marginally improved, patient was still experiencing itchiness/redness/areas hot to touch on legs and side.At 3 week follow-up, hives on patient's arms/legs/side/face were reported to be gone.However, pain in the legs was worse.Physician said the patient was doing well on oral steroids and treatment was being tapered off slowly.All blood work came back normal.Additional blood work performed to test for possible drug induced lupus.Results came back negative.
 
Manufacturer Narrative
Additional information received 11/oct/2016: patient reported to have edema on both legs.Still gets red when standing, itchy and hot.Patient broke out in hives again.Oral steroid (prednisone) dosage was lowered to 40mg from 60mg.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
Patient status update as of (b)(6) 2016: patient had not improved.A rash and/or some inflammatory response had migrated to patient's face.Physician suspected the patient has "chemically induced lupus" however no further testing or work up has been performed.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VENA SEAL CLOSURE SYSTEM
Type of Device
AGENT, OCCLUDING, VASCULAR, PERMANENT
Manufacturer (Section D)
COVIDIEN
951 aviation parkway
morrisville NC 27560
Manufacturer (Section G)
COVIDIEN
951 aviation parkway
morrisville NC 27560
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
091708734
MDR Report Key6016389
MDR Text Key56930312
Report Number2183870-2016-00623
Device Sequence Number1
Product Code PJQ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140018
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,consum
Reporter Occupation Health Professional
Type of Report Initial,Followup,Followup,Followup
Report Date 04/06/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberVS-402
Device Lot Number42356
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 09/13/2016
Initial Date FDA Received10/11/2016
Supplement Dates Manufacturer ReceivedNot provided
Not provided
04/06/2017
Supplement Dates FDA Received11/09/2016
04/26/2017
09/26/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-